Your browser doesn't support javascript.
loading
Temporal Trends in the Prevalence, Treatment and Outcomes of Patients with Acute Coronary Syndrome at High Bleeding Risk.
Arow, Ziad; Ovdat, Tal; Gabarin, Mustafa; Omelchenko, Alexander; Shuvy, Mony; Or, Tsafrir; Assali, Abid; Pereg, David.
Afiliação
  • Arow Z; Cardiology Department, Meir Medical Center, Kfar Saba 4428164, Israel.
  • Ovdat T; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
  • Gabarin M; Department of Cardiology, Sheba Medical Center, Ramat Gan 8452566, Israel.
  • Omelchenko A; Cardiology Department, Meir Medical Center, Kfar Saba 4428164, Israel.
  • Shuvy M; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
  • Or T; Cardiology Department, Meir Medical Center, Kfar Saba 4428164, Israel.
  • Assali A; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
  • Pereg D; Jesselson Integrated Heart Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem 9112102, Israel.
Diagnostics (Basel) ; 12(8)2022 Jul 22.
Article em En | MEDLINE | ID: mdl-35892495
ABSTRACT
(1)

Background:

High bleeding risk is associated with adverse outcomes in ACS patients. We aimed to evaluate temporal trends in treatment and outcomes of ACS patients according to bleeding risk. (2)

Methods:

Included were ACS patients enrolled in ACSIS surveys. Patients were divided into three groups according to enrolment period early (2002−2004), mid (2006−2010) and recent (2012−2018). Each group was further stratified into three subgroups according to CRUSADE bleeding risk score. The primary endpoints were 30-day MACE and 1-year all-cause mortality. (3)

Results:

Included were 13,058 ACS patients. High bleeding risk patients were less frequently treated with guideline-based medications and coronary revascularization. They also had higher rates of 30-day MACE and 1-year all-cause mortality regardless of the enrollment period. Among patients enrolled in early period, 30-day MACE rates were 10.8%, 17.5% and 24.3% (p < 0.001) and 1-year all-cause mortality rates were 2%, 7.7% and 23.6% (p < 0.001) in the low, moderate and high bleeding risk groups, respectively. Among patients enrolled in mid period, 30-day MACE rates were 7.7%, 13.4% and 23.5% (p < 0.001) and 1-year all-cause mortality rates were 1.5%, 7.2% and 22.1% (p < 0.001) in low, moderate and high bleeding risk groups, respectively. For patients enrolled in recent period, 30-day MACE rates were 5.7%, 8.6% and 16.2%, (p < 0.001) and 1-year all-cause mortality rates were 2.1%, 6% and 22.4%, (p < 0.001) in low, moderate and high bleeding risk groups, respectively. These differences remained significant following a multivariate analysis. (4)

Conclusions:

The percentage of patients at high bleeding risk has decreased over the last years. Despite recent improvements in the treatment of ACS patients, high bleeding risk remains a strong predictor of adverse outcomes.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Guideline / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Israel

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Guideline / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Israel